Susmita Ghosh

4 days ago | digitalcommons.library.tmc.edu | Susmita Ghosh

AbstractBackground: KRAS is frequently mutated in the tumors of patients with metastatic colorectal cancer (mCRC) and thus represents a valid target for therapy. However, the strategies of targeting KRAS directly and targeting the downstream effector mitogen-activated protein kinase kinase (MEK) via monotherapies have shown limited efficacy. Thus, there is a strong need for novel, effective combination therapies to improve MEK-inhibitor efficacy in patients with KRAS-mutated mCRC.

4 days ago | digitalcommons.library.tmc.edu | Susmita Ghosh

AbstractMutations in KRAS are found in more than 50% of tumors from patients with metastatic colorectal cancer (mCRC). However, direct targeting of most KRAS mutations is difficult; even the recently developed KRASG12C inhibitors failed to show significant benefit in patients with mCRC. Single agents targeting mitogen-activated protein kinase kinase (MEK), a downstream mediator of RAS, have also been ineffective in colorectal cancer.

Sep 6, 2024 | biorxiv.org | Susmita Ghosh |Fan Fan |Reid T. Powell |Yong D. Park

AbstractBackground: KRAS is frequently mutated in the tumors of patients with metastatic colorectal cancer (mCRC) and thus represents a valid target for therapy. However, the strategies of targeting KRAS directly and targeting the downstream effector mitogen-activated protein kinase kinase (MEK) via monotherapies have shown limited efficacy. Thus, there is a strong need for novel, effective combination therapies to improve MEK-inhibitor efficacy in patients with KRAS-mutated mCRC.

Aug 28, 2024 | digitalcommons.library.tmc.edu | Fan Fan |Susmita Ghosh |Reid T. Powell |Jason Roszik

AbstractMetastatic colorectal cancer (mCRC) is the second leading cause of cancer deaths in the United States. More than 50% of patients with mCRC harbor mutations of the oncogenic driver RAS (KRAS or NRAS). Because directly targeting most mutations of RAS is technically challenging, researchers have concentrated on targeting MEK, a downstream mediator of RAS. However, targeting MEK as single-agent therapy is ineffective in patients with mCRC.

Apr 24, 2024 | medium.com | Susmita Ghosh

Access the best member-only stories. Support independent authors. Listen to audio narrations. Join the Partner Program and earn for your writing. Try for $5/month